Whalesbook
Valuation Ka Chakkar, Profit Ka Kya?
Yaar, Emcure Pharma ke investors aaj thode pareshan hain. Company ka profit toh 24% badhkar ₹243.74 crore ho gaya, lekin stock 6% gir gaya. Scene yeh hai ki valuation bahut zyada lag raha hai aur domestic sales mein thodi kami dikhi hai. Inka P/E ratio lagbhag 50 hai, jo Nifty Pharma sector ke average 35 se kaafi upar hai. Iska matlab market expectations bahut high hain, aur isi wajah se thoda caution dikh raha hai.
International Sales Ne Lagai Daud, India Mein Thandi
Achhi baat yeh hai ki inki international business ne dhamaka kiya hai, 25.7% badhkar ₹1,493 crore ho gayi. Naye products bhi launch kiye hain. Par apna domestic business thoda slow raha, sirf 5.2% growth ke saath ₹977 crore tak pahuncha. Management keh raha hai ki Zuventus Healthcare Ltd portfolio aur sales team mein changes ki wajah se aisa hua hai.
Full Year Results Aur Dividend Ka Update
Pure saal FY26 ki baat karein toh consolidated profit ₹941.27 crore tha aur revenue ₹9,203.54 crore. Company ne ₹3.6 per share ka final dividend bhi recommend kiya hai, bas shareholders ki approval chahiye. MD & CEO Satish Mehta ka kehna hai ki FY26 unke 5-year strategic plan ka ek strong start tha, aur company $1 billion revenue cross kar chuki hai. R&D pipeline, especially complex injectables aur biosimilars, future growth ke liye zabardast hai.
Peers Ke Muqable Valuation Zyada
Jab doosre bade players jaise Sun Pharmaceutical Industries aur Dr. Reddy's Laboratories 30-40 ke P/E par trade kar rahe hain, tab Emcure ka 50 ke kareeb hona thoda alag dikhta hai. Yeh premium valuation suggests karta hai ki market bahut zyada future growth price in kar raha hai. Isi wajah se agar domestic performance mein halki si bhi gadbad hui toh stock mein sharp correction aa sakta hai.
High Valuation Ke Risks
Is high valuation par maintain rehna ek challenge hai. Company ko international growth par depend karna pad raha hai domestic weakness ko cover karne ke liye. Koi bhi operational mistake mehngi pad sakti hai. Analysts bhi filhal 'Hold' rating de rahe hain aur price targets mein zyada upside nahi dekh rahe. Management toh apne R&D aur international strength par focus kar raha hai, aur CEO Satish Mehta ka term bhi agle paanch saal ke liye extend hua hai, jo leadership mein continuity dikhata hai.